HAL (France)open access
Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study
Quality of life, 0, Gastrointestinal manifestations, Vutrisiran, 1, Cardiomyopathy, Transthyretin amyloidosis
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 983906
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.